Please assess the completion status of the following clinical trial:

Trial Title: Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years old Documented HIV-1 infection.~* Has voluntarily signed ICF.~* On HAART ≥ 2 years, without changes in the 24 weeks immediately prior to screening.~* HIV viral load \<50 copies/mL, and never \> 50 copies/mL on 2 consecutive occasions in the last 2 years. CD4 count nadir.~* \> 350 cells/ mm3 Current CD4 count \> 500 cells/ mm3.~* R5 HIV-1 at Screening as defined by proviral DNA genotropism.~Exclusion Criteria:~A subject will NOT be eligible for study participation if he/she meets ANY of the following criteria:~* Any evidence of an active AIDS-defining condition.~* Any significant acute medical illness in the past 8 weeks.~* Women who are pregnant or breastfeeding.~* Use of any of the following within 90 days prior to entry: systemic cytotoxic chemotherapy; investigational agents; immunomodulators (colony-stimulating factors, growth factors, systemic corticosteroids, HIV vaccines, immune globulin, interleukins, interferons); coumadin, warfarin, or other Coumadin derivative anticoagulants. Use of an agent definitely or possibly associated with effects on QT intervals: amiodarone, arsenic trioxide, astemizole, bepridil, chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, probucol, procainamide, quinidine, sotalol, sparfloxacin, terfenadine, thioridazine.~* Receipt of compounds with HDAC inhibitor-like activity, such as valproic acid or nicotinamide within the last 30 days. Potential participants may enroll after a 30-day washout period.~* Known hypersensitivity to the components of gold salt, nicotinamide or its analogs.~* Hepatitis B (HBsAg +) or Hepatitis C (HCV RNA +) infection.~* Known renal insufficiency defined as calculated creatinine clearance (Cockcroft Gault formula) \<60 mL/min.~* Subjects with a laboratory abnormality grade 3 or 4 with the following exceptions: pancreatic amylase, cholesterol, triglyceride, gamma glutamyl transpeptidase, bilirubin.~* Any condition which, in the investigators opinion, could compromise the subject's safety or adherence to the trial protocol.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Antiretroviral Treated (ART) Group (Type: NO_INTERVENTION): Five patients will receive no further intervention this group (control group)
- ART Intensification Group (Type: EXPERIMENTAL): Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks
- ART Intensification + Nicotinamide Group (Type: EXPERIMENTAL): Five patients will receive antiretroviral intensification with maraviroc and dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks.
- ART Intensification + Auranofin Group (Type: EXPERIMENTAL): Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks and the gold salt auranofin for 24 weeks.
- ART Intensification + DC vaccine Group (Type: EXPERIMENTAL): Five patients will receive antiretroviral intensification with dolutegravir and for 48 weeks, and dendritic cell vaccine.
- Multi Interventional Group (Type: EXPERIMENTAL): Five patients will receive antiretroviral intensification with dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks, and gold salt for 24 weeks and dendritic cell vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).